Rockefeller Capital Management L.P. Neurocrine Biosciences Inc Transaction History
Rockefeller Capital Management L.P.
- $42.4 Billion
- Q2 2025
A detailed history of Rockefeller Capital Management L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 113,229 shares of NBIX stock, worth $15.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
113,229
Previous 113,229
-0.0%
Holding current value
$15.5 Million
Previous $14.2 Million
-0.0%
% of portfolio
0.03%
Previous 0.04%
Shares
24 transactions
Others Institutions Holding NBIX
# of Institutions
657Shares Held
101MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.94 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.34 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$761 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$610 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$422 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...